Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 19Withdrawn 2Terminated 2Active not recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Gynecologic 2Genitourinary 1Breast 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × veliparib × Gynecologic × Clear all
NCT02470585 2024-10-26

VELIA

AbbVie

Phase 3 Terminated
1,140 enrolled 29 charts
Gynecologic

Ovarian Neoplasms

NCT01233505 2014-04-02

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Terminated
16 enrolled
BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡